60 related articles for article (PubMed ID: 38676754)
21. Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma.
Cigliano A; Pilo MG; Mela M; Ribback S; Dombrowski F; Pes GM; Cossu A; Evert M; Calvisi DF; Utpatel K
Medicina (Kaunas); 2019 Dec; 56(1):. PubMed ID: 31861475
[No Abstract] [Full Text] [Related]
22. Identification of key genes in non-small cell lung cancer by bioinformatics analysis.
Zhang L; Peng R; Sun Y; Wang J; Chong X; Zhang Z
PeerJ; 2019; 7():e8215. PubMed ID: 31844590
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway.
Chen S; Zhou Q; Guo Z; Wang Y; Wang L; Liu X; Lu M; Ju L; Xiao Y; Wang X
J Cell Mol Med; 2020 Jan; 24(2):1804-1821. PubMed ID: 31821699
[TBL] [Abstract][Full Text] [Related]
24. Higher maternal embryonic leucine zipper kinase mRNA expression level is a poor prognostic factor in non-small-cell lung carcinoma patients.
Zang X; Qian C; Ruan Y; Xie J; Luo T; Xu B; Jiang J
Biomark Med; 2019 Nov; 13(16):1349-1361. PubMed ID: 31599664
[No Abstract] [Full Text] [Related]
25. Metformin Modulates Cyclin D1 and P53 Expression to Inhibit Cell Proliferation and to Induce Apoptosis in Cervical Cancer Cell Lines.
Yudhani RD; Astuti I; Mustofa M; Indarto D; Muthmainah M
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1667-1673. PubMed ID: 31244286
[TBL] [Abstract][Full Text] [Related]
26. Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
Turner NC; Liu Y; Zhu Z; Loi S; Colleoni M; Loibl S; DeMichele A; Harbeck N; André F; Bayar MA; Michiels S; Zhang Z; Giorgetti C; Arnedos M; Huang Bartlett C; Cristofanilli M
J Clin Oncol; 2019 May; 37(14):1169-1178. PubMed ID: 30807234
[TBL] [Abstract][Full Text] [Related]
27. MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells.
Ren L; Deng B; Saloura V; Park JH; Nakamura Y
Oncol Rep; 2019 Apr; 41(4):2540-2548. PubMed ID: 30720113
[TBL] [Abstract][Full Text] [Related]
28. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.
Chlenski A; Park C; Dobratic M; Salwen HR; Budke B; Park JH; Miller R; Applebaum MA; Wilkinson E; Nakamura Y; Connell PP; Cohn SL
Mol Cancer Ther; 2019 Mar; 18(3):507-516. PubMed ID: 30674566
[TBL] [Abstract][Full Text] [Related]
29. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Bray F; Ferlay J; Soerjomataram I; Siegel RL; Torre LA; Jemal A
CA Cancer J Clin; 2018 Nov; 68(6):394-424. PubMed ID: 30207593
[TBL] [Abstract][Full Text] [Related]
30. MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.
Li G; Yang M; Zuo L; Wang MX
Oncol Lett; 2018 Jun; 15(6):9934-9940. PubMed ID: 29805690
[TBL] [Abstract][Full Text] [Related]
31. Correction to: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis.
Li Y; Li Y; Chen Y; Xie Q; Dong N; Gao Y; Deng H; Lu C; Wang S
Cancer Cell Int; 2018; 18():55. PubMed ID: 29652412
[TBL] [Abstract][Full Text] [Related]
32. MELK is a novel therapeutic target in high-risk neuroblastoma.
Guan S; Lu J; Zhao Y; Yu Y; Li H; Chen Z; Shi Z; Liang H; Wang M; Guo K; Chen X; Sun W; Bieerkehazhi S; Xu X; Sun S; Agarwal S; Yang J
Oncotarget; 2018 Jan; 9(2):2591-2602. PubMed ID: 29416794
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.
Wang LY; Cui JJ; Guo AX; Yin JY
Onco Targets Ther; 2018; 11():529-538. PubMed ID: 29416353
[TBL] [Abstract][Full Text] [Related]
34. Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis.
Piao J; Sun J; Yang Y; Jin T; Chen L; Lin Z
Gene; 2018 Mar; 647():306-311. PubMed ID: 29305979
[TBL] [Abstract][Full Text] [Related]
35. MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway.
Janostiak R; Rauniyar N; Lam TT; Ou J; Zhu LJ; Green MR; Wajapeyee N
Cell Rep; 2017 Dec; 21(10):2829-2841. PubMed ID: 29212029
[TBL] [Abstract][Full Text] [Related]
36. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Postmus PE; Kerr KM; Oudkerk M; Senan S; Waller DA; Vansteenkiste J; Escriu C; Peters S;
Ann Oncol; 2017 Jul; 28(suppl_4):iv1-iv21. PubMed ID: 28881918
[No Abstract] [Full Text] [Related]
37. MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.
Pitner MK; Taliaferro JM; Dalby KN; Bartholomeusz C
Expert Opin Ther Targets; 2017 Sep; 21(9):849-859. PubMed ID: 28764577
[TBL] [Abstract][Full Text] [Related]
38. The Eighth Edition Lung Cancer Stage Classification.
Detterbeck FC; Boffa DJ; Kim AW; Tanoue LT
Chest; 2017 Jan; 151(1):193-203. PubMed ID: 27780786
[TBL] [Abstract][Full Text] [Related]
39. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
[TBL] [Abstract][Full Text] [Related]
40. Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
Minguet J; Smith KH; Bramlage P
Int J Cancer; 2016 Jun; 138(11):2549-61. PubMed ID: 26537995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
